<- Go Home
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Market Cap
$766.9M
Volume
846.0K
Cash and Equivalents
$225.5M
EBITDA
-$41.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$15.10
52 Week Low
$2.31
Dividend
N/A
Price / Book Value
2.89
Price / Earnings
-11.09
Price / Tangible Book Value
2.89
Enterprise Value
$535.7M
Enterprise Value / EBITDA
-13.02
Operating Income
-$41.8M
Return on Equity
34.18%
Return on Assets
-20.52
Cash and Short Term Investments
$232.1M
Debt
$1.0M
Equity
$228.9M
Revenue
N/A
Unlevered FCF
-$25.4M
Sector
Biotechnology
Category
N/A